MARK GOODRICH: Open Payments
NPI 1356447882 · CLINTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 28 payments from 13 companies in 2025. Trend: 2023 $829 · 2024 $1,550 · 2025 $597
Food & beverage: $597
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $144 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $78 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| ABBVIE INC. | 4 | $70 |
| Lilly USA, LLC | 3 | $47 |
| Corcept Therapeutics | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Medtronic, Inc. | 1 | $23 |
| Biogen, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
Products named: BREZTRI, Kerendia, QULIPTA, Sunosi, Korlym, REXULTI, MOUNJARO, INCEPTIV.
Industry payments across UT — which companies pay providers there.
